You are here

Home » Content

KEDİ MEME FIBROEPITELYAL HİPERPLAZISİNİN CABERGOLIN VE AGLEPRISTON KOMBINASYONU İLE TEDAVİSİ

Treatment of Feline Mammary Fibroepithelial Hyperplasia with the Combination of Aglepristone and Cabergoline

Journal Name:

  • İstanbul Üniversitesi Veteriner Fakültesi Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
A case of fibroepithelial mammary hyperplasia in a two years old, intact, tabby female cat that showed oestrus 1 month ago was treated with the combination of aglepristone (Alizine, Virbac®) and cabergoline (Galastop, Ceva®) administrations. On the day of treatment, serum progesterone concentration was detected as 2,96 ng/ml and serum oestradiol concentration was below 5,0 pg/ml. The cat was treated with subcutaneous (SC) injections of aglepristone (Alizine, Virbac®) 15 mg/kg body weight (b.w.) on two subsequent days per week for three weeks and 5 µg/kg b.w per a day, per os (PO) cabergoline (Galastop, Ceva®) administration was accompanied to this treatment on the first week for seven days. On the examination at the end of the third week, there was a marked regression of the mammary glands and the milk secretion ceased. Six weeks after the initiation of treatment, mammary glands were completely regressed and serum progesterone and oestradiol concentrations were 0.142 ng/ml, and <5pg/ml respectively. It is determined that in such cases which is associated with milk secretion, successful results can be achieved by using aglepristone (Alizine, Virbac®) and cabergoline (Galastop, Ceva®) together.
Bookmark/Search this post with
Abstract (Original Language): 
Fibroepitelyal meme hiperplazi olgusu; kısırlaştırılmamış, 2 yaşlı, bir ay önce östrus göstermiş tekir dişi bir kedide aglepriston (Alizine, Virbac®) ve cabergolin (Galastop, Ceva®) kombinasyonu ile tedavi edildi. Tedavi günü, serum progesteron konsantrasyonu 2,96 ng/ml ve serum östradiol konsantrasyonu 5 pg/ml’den düşük olarak tespit edildi. Kedi, 15 mg/kg canlı ağırlığa (c.a.) aglepriston (Alizine, Virbac®) ile haftada iki gün üst üste 3 hafta boyunca ve bu tedaviye ek olarak cabergolin (Galastop, Ceva®) 5 µg/kg c.a. ile hergün günde 1 defa, per os (PO) birinci haftada uygulandı Üç hafta sonundaki muayenede, meme bezlerinde belirgin küçülme ve süt salgısının kesildiği saptandı. Tedavi başlangıcından 6 hafta sonra, meme bezlerinin tamamen küçüldüğü ve serum progesteron ve östradiol konsantrasyonlarının sırasıyla 0.142 ng/ml ve <5pg/ml olduğu saptandı. Süt salgısının mevcut olduğu bu tarz olgularda aglepriston (Alizine, Virbac®) ve cabergolinin (Galastop, Ceva®) beraber kullanımı ile başarılı sonuçlar alınabileceği belirlendi
FULL TEXT (PDF): 
PDF icon arastirmax-kedi-meme-fibroepitelyal-hiperplazisinin-cabergolin-aglepriston-kombinasyonu-ile-tedavisi.pdf
  • 1
69-73
  • English

REFERENCES

References: 

Allen, H., 1973. Feline mammary hypertrophy.
Veterinary Pathology 10, 501-508.
Arbeiter, K., Brass, W., Ballabio, R., Jöchle, W.,
1998. Treatment of pseudopregnancy in the
bitch with cabergoline, an ergoline derivate.
Journal of Small Animal Practice 29, 781-788.
Baştan, A., Fındık, M., Erünal, N., Aslan, S.,
Kılıçoğlu, Ç., 1998. The use of cabergoline for
the treatment of pseudopregnancy in dogs with
the purpose of suppressing lactation.
Reproduction in Domestic Animal 33,49-53.
Baştan, A., Özenç, E., Yağcı, İ.P., Beceriklisoy, H.B.,
2004. Bir kedide meme hipertrofisi olgusu.
Ankara Üniversitesi Veteriner Fakültesi Dergisi
51, 79-82.
Bethlehem, M., Van der I, R.J.T., 1993. Feline fibro-epitheliale hyperplasie bij drie gecastreerde
katers na behandeling met progestativa.
Tijdschr Diergeneeskd. 118, 650-652.
Görlinger, S., Kooistra, H.S., Van den Broek, A.,
Okkens, A.C., 2002. Treatment of
fibroadenomatous hyperplasia in cats with
aglepristone. Journal of Veterinary Internal
Medicine 16, 710-713.
Johnston, S.D., Kustritz, M.V.R., Olson, P.N.S.,
2001. Mammary hypertropy. In: Johnston,
S.D., Kustritz, M.V.R., Olson, P.N.S. (Eds.),
Canine and feline theriogenology. Philadelphia,
W.B. Saunders Company, pp. 474-477.
Keskin, A., Yılmazbaş, G., Şimşek, G., İntaş, K.S.,
2008. Mammary hyperplasia in a pregnant
queen. Australian Veterinary Practitoner 38, 75.
Loretti, A.P., Ilha, M.R.S., Breitsameter, I., Faraca,
C.S., 2004. Clinical and pathological study of
feline mammary fibroadenomatous change
associated with depot medroxyprogesterone
acetate therapy. Arquivo Brasilero de Medicina
Veterinariae Zootecnia. 56(2), 270-274.
Nak, D., Nak, Y., İntaş, K.S., Kumru, İ.H., 2004.
Treatment of feline mammary
fibroadenomatous hyperplasia with
aglepristone. Australian Veterinary Practitoner
34(4), 161-162.
Sontas, B.H., Turna, Ö., Uçmak, M., Ekici, H., 2008.
What is your diagnosis. Journal of Small
Animal Practice 49, 545-547.
Verstegen, J.P., 1998. Pharmacological control of
reproduction in the cat. In: England, G., Harvey,
M. (Eds.), Manuel of small animal reproduction
and neonatology. BSAVA., U.K, pp. 219-226.
Vitasek, R., Dendisova, H., 2006. Treatment of feline
fibroepithelial hyperplasia following a single
injection of proligestone. Acta Veterinaria Brno
75, 295-297.
Wehrend, A., Hospes, R., Gruber, A.D., 2001.
Treatment of feline fibroadenomatous
hyperplasia with a progesterone antagonist.
Veterinary Record 148, 346-347.

Thank you for copying data from http://www.arastirmax.com